YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Royalty Pharma has delivered a strong share price run in recent years, which naturally puts fresh attention on what investors are paying for its earnings today. With the stock now around US$58.52, the key issue is how that outcome lines up…
Royalty Pharma (RPRX) is set to present at the Bank of America Global Healthcare Conference in London on September 23, 2026. The appearance will put its biopharmaceutical royalty model back in front of institutional investors. Recent tradi…
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
Royalty Pharma plc NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program…
Donation marks a new phase for Blood Cancer United's venture philanthropy program, with returns reinvested to support future therapies NEW YORK, NY and WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Blood Cancer United and Royalty Pharma today…
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets. On Friday, the Dow Jones Industrial…
Investors choosing between Amgen (NASDAQ:AMGN) and Revolution Medicines (NASDAQ:RVMD) must weigh established cash flows against high-stakes clinical potential. Which of these healthcare players is the better addition to your portfolio toda…
Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprot…
Royalty Pharma plc NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Morgan Stanley 24th An…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amarin (AMRN) been one of those stocks this year? A quick glance at the company's year-to-date performance in compariso…
The S&P 500 Index ($SPX) (SPY) closed down -0.58% on Tuesday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.12%. E-mini S&P futures (ESU26) fell -0.57%, and Septemb…
The S&P 500 Index ($SPX) (SPY) is down -0.32% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.04%. E-mini S&P futures (ESU26) are down -0.33%, and September E-mini Nas…
The S&P 500 Index ($SPX) (SPY) is down -0.34% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.83%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.19%. E-mini S&P futures (ESU26) are down -0.41%, and September E-mini Nas…
On Tuesday, Novartis AG(NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history. Phase 3 HARBOR Trial Misses Primary Endpoint On Tuesday, the company shared data from the global Phase 3 HARBOR st…
Royalty Pharma plc NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied i…
On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma's sec…
In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy target…
Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend. A well-li…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current mark…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agree…
Royalty Pharma plc NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (P…
Zealand Pharma Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million fo…
This article first appeared on GuruFocus. Cash and Investments: $3.9 billion at the end of Q2 2026, including $2.2 billion in gross proceeds from public offerings and a $250 million royalty tranche from Royalty Pharma. R&D Expenses: $395 m…
This article first appeared on GuruFocus. Portfolio Receipts: Grew 6% in Q2 2026 to $773 million, ahead of expectations. Royalty Receipts: Grew 14% in Q2 2026, driven by strong performances from Tremfya, Voranigo, Emdeltra, and Evrysdi. To…
For the quarter ended June 2026, Royalty Pharma (RPRX) reported revenue of $773 million, up 6.3% over the same period last year. EPS came in at $1.32, compared to $1.14 in the year-ago quarter. The reported revenue compares to the Zacks Co…
Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items…
(RTTNews) - Royalty Pharma plc (RPRX) will host a conference call at 8:00 AM ET on August 5, 2026, to discuss Q2 26 earnings results. To access the live webcast, log on to https://www.royaltypharma.com/investors/events/ The views and opini…
Royalty Pharma plc Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million t…
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * Shopify (SHOP [https://seekingalpha.c…
Analysts on Wall Street project that Royalty Pharma (RPRX) will announce quarterly earnings of $1.27 per share in its forthcoming report, representing an increase of 11.4% year over year. Revenues are projected to reach $761.4 million, inc…
Royalty Pharma plc NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Royalty Pharma dividend decision puts income focus in the spotlight Royalty Pharma (RPRX) has affirmed a third quarter…
Wall Street expects a year-over-year increase in earnings on higher revenues when Iovance Biotherapeutics (IOVA) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company…
(RTTNews) - The following biotech stocks reached a 52-week high on July 29, 2026, driven by key catalysts such as the release of second quarter financial results and ongoing clinical research. Anika Therapeutics Inc. (ANIK) Anika Therapeut…
The market expects Royalty Pharma (RPRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company…
Royalty Pharma plc NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including…